跳至主要内容
临床试验/DRKS00027025
DRKS00027025已完成4 期

Prospective randomized clinical trial comparing early rotation of two extended depth of focus intraocular lenses - VENUS toric

Carl Zeiss Meditec AG0 个研究点目标入组 153 人开始时间: 2021年12月28日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
153

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
45 Years 至 one(—)
性别
All

入选标准

  • 1. Patient informed of the consequences and constraints of the Clinical Investigational Plan and who has given his/her written informed consent
  • 2. Patients of any gender, aged 45 or older
  • 3. Assured follow-up examinations
  • 4. Eyes with clinically significant age related cataract requiring surgical treatment, otherwise healthy
  • 5. Corrected distance visual acuity projected to be better than 0.2 logMAR after the cataract surgery, as determined by Investigator’s medical judgment
  • 6. Calculated IOL power is within SE +14.0 D and +30.0 D (in 0.5 diopter increments) and between a cylindrical range of +1.0 D to +4.0 D, in the study eye(s).
  • 7. Uni- and/or bilaterally regular corneal astigmatism confirmed by topography measurement
  • 8. Cataract density compatible with biometry measurement
  • 9. In case both eyes will be included, patient agreed to have surgery of the second eye performed between 1 day and 1 month after the surgery of the first eye.

排除标准

  • 10. Patients unable to meet the limitations of the Clinical Investigational Plan or likely of non-cooperation during the trial
  • 11. Patients whose freedom is impaired by administrative or legal order
  • 12. Current systemic or ocular pharmacotherapy that may interfere with the conductance of the trial in the opinion of the investigator. (e.g. Chloroquine and Hydroxychloroquine (Maculopathy), Tamoxifen (Retinopathy), Ethambutol (Optic Neuropathy)
  • 13. Ocular disorders, other than cataract, that could potentially cause future acuity loss to a level of 0.20 logMAR (corrected) or worse in either eye
  • 14. Have atonic pupil or physiologically small pupil (unable to dilate to at least 5 mm)
  • 15. Any anterior segment pathology that could significantly affect outcomes (e.g. chronic or recurrent uveitis, iritis, aniridia, rubeosis iridis, etc.)
  • 16. Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism, clinically significant corneal membrane dystrophies)
  • 17. Any condition in the study eye that could affect IOL stability (e.g. zonular dialysis, evident zonular weakness or dehiscence, Floppy iris syndrome etc.)
  • 18. History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmus, epiretinal membrane, Choroidal hemorrhage etc.) in the study eyes that could alter or limit final postoperative visual prognosis
  • 19. Pseudoexfoliation syndrome (according to investigator decision)
  • 20. Pathologic miosis or Pharmacotherapy with miotic agent
  • 21. Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment.
  • 22. All kind of infections (acute ocular disease, external / internal infection, systemic infection)
  • 23. Traumatic cataract
  • 24. Monophthalmic patient
  • 25. Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus
  • 26. Patient expected to require retinal laser treatment before the end of the last follow-up examination
  • 27. Patient expected to require refractive laser treatment / refractive laser touch-up before the end of the last follow-up examination
  • 28. Previous intraocular and corneal / refractive surgery
  • 29. Dementia
  • 30. Previous use of cytotoxic drugs or total body irradiation within last 2 years
  • 31. Any other pathology or condition presenting, according to the investigator opinion, a risk for the patient
  • 32. Pregnancy and / or lactation period

研究者

相似试验